|
Protocol
( For Research Use Only )
|
| 1.
Dispense 100µl
of the
standards, controls, and samples into their designated
wells. |
| 2.
Seal the plate and incubate for 2hours at the room
temperature. |
 |
| 3.
Wash the plate 3 times with
Wash buffer. |
| 4.
Add 100µl
of the diluted Biotinylated-
antibody to each well. |
| 5.
Seal the plate and incubate it for 2hours at the room
temperature. |
| 6.
Wash the plate 3 times with
wash buffer. |
| 7.
Add 100µl
of the diluted Streptavidin-HRP conjugate to each well. |
| 8.
Seal the plate and incubate it for 30min at the room
temperature. |
| 9.
Wash the plate more than
4 times with
wash buffer. |
| 10.
Immediately dispense 100µl
TMB substrate solution (TMB A + TMB B) into each
well and incubate
at room temperature for 15-30mins. |
| 11.
Add 50µl
of Stop Solution to each well. |
| 12.
Read absorbance with a microplate reader at 450nm. |
|
Reference
|
| Avirutnan,
P., P. Malasit, B. Seliger, S. Bhakdi, and M. Husmann
(1998) Dengue virus infection
of
human endothelial cells leads to chemokine production,
complement activation, and apoptosis. J.Immunol
161(11):6338-46. |
| Aziz,
N., et al. (1999)
Stability of Plasma Levels of Cytokines and
Soluble Activation Markers in Patients with Human
Immunodeficiency Virus Infection. Journal of Infectious
Disease. 179:843-8. |
| Bienvenu,
J., et al. (1993)
Analytical performances of commercial ELISA kits
for IL-2, IL-6 and TNF-alpha.
A WHO study.
Eur. Cytokine Netw.
4(6);447-451. |
| Oliver,
S.J., A. Moreira, and G. Kaplan (2000) Immune
stimulation in scleroderma patients treated with
thalidomide. Clinical Immunology 97(2):1980120.
|